After publication of our article [1], we were made aware of some errors in our figures and tables. There have been no changes to the interpretation of the results, conclusions and applications of our article.
In Fig. 2 and Fig. 3, for Perez-Padilla 2009, the events/total in the corticosteroids and control groups should be 3/5 and 4/13, respectively, instead of 4/7 and 8/11 in the original article. For Viasus 2011, the events/total in the corticosteroids and control groups should be 3/37 and 4/160, respectively, instead of 3/37 and 7/160 in the original article. Thus, in our final systematic review and meta-analysis, 2,562 patients were treated with corticosteroids and 3,986 with non-corticosteroids. The statistical heterogeneity in the analysis of the effect of corticosteroids on mortality should be (I2=83%, P<0.00001), instead of (I2=84%, P<0.00001) in the original article. And, the results of the analysis about mortality should be (RR 1.91, 95% CI 1.42~2.55, Z=4.33, P<0.0001), instead of (RR 1.75, 95% CI 1.30~2.36, Z=3.71, P=0.0002). Similarly, the results of the subgroup mortality in H1N1 patients should be (RR 1.92, 95% CI 1.23~3.02, Z=2.85, P=0.004), rather than (RR 1.69, 95% CI 1.15~2.47, Z=2.68, P=0.007).
Otherwise, Lee 2014 should be Lee 2015.
Fig. 2
Effect of corticosteroids on mortality
Fig. 3
Subgroup analysis regarding the effect of corticosteroids on mortality in patients with H1N1
×
×
In Fig. 5, the SD for the corticosteroids and control groups in Brun-Buisson’s study should be 19.26 and 14.07, respectively, instead of 14.07 and 19.26 in the original article. Thus, the statistical heterogeneity of the analysis on ICU LOS should be (I2=30%, P=0.23), instead of (I2=38%, P=0.21). And the result of this analysis should be (MD 2.12, 95% CI 1.15~3.09, Z=4.30, P<0.0001), rather than (MD 2.14, 95% CI 1.17~3.10, Z=4.35, P<0.0001) in the original article.
Fig. 5
Effect of corticosteroids on ICU LOS
×
Anzeige
In Fig. 6, the study ID “Dias 2012” should be “Viasus 2011”.
Fig. 6
Effect of corticosteroids on the rate of secondary infection
×
In table 1, the antiviral drug in Lee’s study should be NR.
In table 2, for Brun-Buisson’s study, the Male (n, %) in the corticosteroids group should be 36(43.4), and 69(55.2) in the control group. For Moreno’s study, the APACHE II in the corticosteroids group should be 15(10-20) and 14(10-19) in the control group.
And, the age and male in the control group of Viasus’s study should be NR.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.
Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.
Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.
Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.
Update AINS
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
